Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Stok Raporu

Piyasa değeri: US$3.4m

Biodexa Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Biodexa Pharmaceuticals' CEO is Stephen Stamp, appointed in Sep 2019, has a tenure of 5.17 years. total yearly compensation is £252.00K, comprised of 99.2% salary and 0.8% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $5.84. The average tenure of the management team and the board of directors is 2.4 years and 7.5 years respectively.

Anahtar bilgiler

Stephen Stamp

İcra Kurulu Başkanı

UK£252.0k

Toplam tazminat

CEO maaş yüzdesi99.2%
CEO görev süresi5.2yrs
CEO sahipliği0.0002%
Yönetim ortalama görev süresi2.4yrs
Yönetim Kurulu ortalama görev süresi7.5yrs

Son yönetim güncellemeleri

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

Midatech surges on the promise of drug delivery system

Jun 17

CEO Tazminat Analizi

Stephen Stamp'un ücretlendirmesi Biodexa Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-UK£7m

Mar 31 2024n/an/a

-UK£7m

Dec 31 2023UK£252kUK£250k

-UK£7m

Sep 30 2023n/an/a

-UK£8m

Jun 30 2023n/an/a

-UK£8m

Mar 31 2023n/an/a

-UK£8m

Dec 31 2022UK£238kUK£236k

-UK£8m

Sep 30 2022n/an/a

-UK£7m

Jun 30 2022n/an/a

-UK£5m

Mar 31 2022n/an/a

-UK£5m

Dec 31 2021UK£329kUK£187k

-UK£5m

Sep 30 2021n/an/a

-UK£7m

Jun 30 2021n/an/a

-UK£8m

Mar 31 2021n/an/a

-UK£15m

Dec 31 2020UK£193kUK£175k

-UK£22m

Jun 30 2020n/an/a

-UK£22m

Mar 31 2020n/an/a

-UK£16m

Dec 31 2019UK£207kUK£50k

-UK£9m

Tazminat ve Piyasa: Stephen's total compensation ($USD325.61K) is below average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Stephen's compensation has increased whilst the company is unprofitable.

CEO

Stephen Stamp (62 yo)

5.2yrs

Görev süresi

UK£252,003

Tazminat

Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Biodexa Pharmaceuticals Plc (formerly known as Midatech Pharma plc) since September 9, 2019. He serves as Chief Executive Officer at B...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Stephen Stamp
CEO, CFO5.2yrsUK£252.00k0.00017%
$ 5.8
Daniel Palmer
Vice President of Technology3.8yrsVeri yokVeri yok
Nicola Tuckwell
VP & Head of Clinical Operationsless than a yearVeri yokVeri yok
Steve Ellul
Chief Business Officerless than a yearVeri yokVeri yok
Fiona Sharp
Group Financial Controllerno dataVeri yokVeri yok

2.4yrs

Ortalama Görev Süresi

Deneyimli Yönetim: BDRX's management team is considered experienced (2.4 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Stephen Stamp
CEO, CFO5.2yrsUK£252.00k0.00017%
$ 5.8
Simon Turton
Senior Independent Non-Executive Director9.9yrsUK£31.92k0.00017%
$ 5.8
Stephen Parker
Independent Non-Executive Chairman2.4yrsUK£82.00kVeri yok
Daniel McCurdy
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Sijmen de Vries
Independent Non-Executive Director20.1yrsUK£31.92k0.00017%
$ 5.8
Michael Natan
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Francesco Stellaci
Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
David Male
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Lorraine O'Driscoll
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Soledad Penades
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Jean-Christophe Roux
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Silke Krol
Member of Scientific Advisory Boardno dataVeri yokVeri yok

7.5yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BDRX's board of directors are considered experienced (7.5 years average tenure).